Abstract
Schizophrenia and psychosis in general, are health problems for a lot of patients around the world. The causes of developing those mental illnesses are still unknown. Several hypotheses have been introduced to justify these malfunctions. Our article focuses on the glutaminergic hypothesis and how it might lead to the onset of the disorders. The NMDA receptor controls the release of acetylcholine, GABA, and dopamine, while at the same time, it downregulates the 5HT1A receptor and upregulates the 5HT2A. While NMDA antagonists can produce psychosis, NMDA agonists might have the opposite effect. To that end, we found a ligand called 2-Phenylcyclohexane-1-carboxamide and studied its pharmacological properties through the use of the program mcule. What we found was an affinity for the NMDA receptor, the GABA transporter, and acetylcholinesterase. We urge researchers to study further this particular molecule in hopes of identifying all possible in silico interactions and measuring their respective Kds.